Syntal Capital Partners’s AbbVie ABBV Stock Holding History

Syntal Capital Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-7,986	Closed	-$1.08M	–	107
2023 Q2	$1.08M	Sell	7,986 -370	-4%	-$54.3K	0.43%	72
2023 Q1	$1.33M	Buy	8,356 +292	+4%	+$44.6K	0.49%	55
2022 Q4	$1.3M	Buy	8,064 +253	+3%	+$38.8K	0.52%	43
2022 Q3	$1.05M	Buy	7,811 +72	+0.9%	+$10.3K	0.43%	50
2022 Q2	$1.19M	Sell	7,739 -9,464	-55%	-$1.45M	0.52%	39
2022 Q1	$2.79M	Buy	+17,203	New	+$2.5M	1.09%	19
2015 Q4	–	Sell	-150	Closed	-$8K	–	69
2015 Q3	$8K	Hold	150	–	–	0.01%	135
2015 Q2	$10K	Hold	150	–	–	0.01%	155
2015 Q1	$8K	Sell	150 -1,800	-92%	-$109K	0.01%	163
2014 Q4	$127K	Hold	1,950	–	–	0.07%	89
2014 Q3	$112K	Hold	1,950	–	–	0.06%	99
2014 Q2	$101K	Buy	+1,950	New	+$102K	0.05%	111

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Syntal Capital Partners's ABBV Position: Q3 2023 in Review

Syntal Capital Partners sold out of AbbVie (ABBV) in Q3 2023, closing a stake of 7,986 shares — an estimated $1.08M sold.

Syntal Capital Partners first reported a position in ABBV in Q2 2014 and held it in 12 quarters. The position peaked at $2.79M in Q1 2022. 3,112 funds tracked by Wall St. Rank hold ABBV as of Q3 2023.

Syntal Capital Partners reported no remaining AbbVie position as of Q3 2023 after selling out during the quarter.
Syntal Capital Partners sold 7,986 AbbVie shares in Q3 2023, an estimated $1.08M.
Syntal Capital Partners first reported a position in AbbVie in Q2 2014 and held it in 12 quarters.
Syntal Capital Partners's AbbVie position peaked at $2.79M in Q1 2022.
3,112 funds tracked by Wall St. Rank held AbbVie as of Q3 2023.

Based on Syntal Capital Partners's 13F filing for Q3 2023, filed 3 Nov 2023.